Gilead Sciences, Inc. (NASDAQ:GILD) reported that James Meyers, EVP, Commercial Operations, has taken the decision to retire from his current role, effective immediately. Mr. Meyers joined company as a regional sales director in 1996 and was appointed to his current profile in 2016. After a brief family leave in 2018, Mr. Meyers reported his decision to retire. It should be noted that Meyers will continue to be associated with the firm in an advisory capacity, to advice on priority projects and to help with facilitating the transition and identifying his successor. The firm will commence a search for his successor in the imminent weeks.
John Milligan, PhD, the CEO and President of Gilead Sciences, expressed that Meyers has played a vital role in directing company through a period of remarkable change and growth, and he has formed an exceptional team. He has confidence in the ability of the team to execute against their ambitious goals and grateful to Meyers for his commitment to help them through this transition. They wish Meyers the very best, and appreciate his contributions to company over the preceding 22 years.
In unrelated news, Kite, a Gilead firm and Sangamo Therapeutics Inc (NASDAQ:SGMO) reported that the firms have finalized a worldwide collaboration using latter’s zinc finger nuclease technology platform for the advancement of next-gen ex vivo cell treatments in oncology. Kite will utilize ZFN technology to modify genes to advance next-generation cell therapies for allogeneic and autologous use in curing different type of cancers. Allogeneic cell treatments from renewable stem cells or from healthy donor cells would offer a potential treatment alternative that can be accessed within the oncology infusion facility, thus lowering the time to infusion.
In the last trading session, the stock price of Gilead Sciences gained more than 1% to close the day at $80.91.